PoC Test R&D Complicated By Emergency Consent Provisions – Genzyme Rep
This article was originally published in The Gray Sheet
Executive Summary
FDA emergency research regulations requiring a therapeutic window to obtain informed consent may slow down development of rapid diagnostics for stroke and heart attack, according to Genzyme VP-Regulatory Affairs Robert Yocher
You may also be interested in...
IRB Costs Would Be Recoupable As Direct Costs Under Sen. Kennedy Bill
Institutional review board operational expenses could be billed as direct costs on federal grants, ensuring the review bodies receive adequate resources under legislation introduced by Sen. Edward Kennedy (D-Mass.) Oct. 4
Genzyme's Wyntek Buy To Accelerate Point-Of-Care Stroke Test R&D
Genzyme General's $65 mil. cash acquisition of rapid point-of-care test developer Wyntek Diagnostics will broaden Genzyme's existing rapid test portfolio and accelerate development of a quantitative rapid stroke panel, Genzyme says. Announced May 8, the deal is expected to close by July 1.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.